Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Centessa Pharmaceuticals plc (NASDAQ: CNTA) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $26.00 price target on the stock, up previously from $11.00.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is now covered by analysts at B. Riley. They set a "buy" rating and a $33.00 price target on the stock.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at BMO Capital Markets from $20.00 to $35.00. They now have an "outperform" rating on the stock.
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares [Yahoo! Finance]